Nighan Warren JR 4
4 · ANGIODYNAMICS INC · Filed Jul 24, 2026
Research Summary
AI-generated summary of this filing
AngioDynamics (ANGO) SVP Warren Nighan Receives 5,694 Shares; Sells 1,671
What Happened
Warren Nighan Jr., Senior VP of Quality and Regulatory at AngioDynamics (ANGO), had performance share units vest on July 22, 2026. 5,694 shares of common stock were issued to him upon settlement of the earned PSUs. To satisfy tax withholding obligations, 1,671 of those shares were withheld/sold at $13.82 per share for a tax payment of $23,093. The original target grant was 20,052 PSUs; the remainder were forfeited.
Key Details
- Transaction date: July 22, 2026; Form 4 filed July 24, 2026 (timely filing).
- Issued/Acquired: 5,694 shares via vesting/settlement of PSUs (reported as derivative exercise/settlement, $0 acquisition price for award).
- Tax withholding: 1,671 shares surrendered/ disposed at $13.82 per share to satisfy tax liability = $23,093. (Transaction code F = tax withholding)
- Forfeiture/cancellation: 14,358 of the original 20,052 target PSUs were not earned and were forfeited/cancelled (per footnote).
- Shares owned after the transaction: not disclosed in the provided filing.
- Footnotes: PSUs were granted July 19, 2023 with performance metrics over fiscal 2024–2026; up to 200% of target could be earned; 20% of earned shares subject to TSR modifier vs peers.
Context
This was a standard settlement of performance-based equity rather than an open-market purchase or discretionary sale. The withholding of shares to cover taxes is routine and does not, by itself, indicate a buy/sell signal. The filing shows earned PSUs converted to shares and the unearned portion cancelled per the plan metrics.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-07-22+5,694→ 89,786 total - Tax Payment
Common Stock
[F2]2026-07-22$13.82/sh−1,671$23,093→ 88,115 total - Exercise/Conversion
Performance Right
[F3]2026-07-22−20,052→ 0 total→ Common Stock (20,052 underlying)
Footnotes (3)
- [F1]This acquisition of 5,694 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
- [F2]The exempt disposition of 1,671 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
- [F3]On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.